Role of Toll-like receptors in COVID-19 pathogenesis

Introduction. This review summarizes the available information on the role of Toll-like receptors (TLRs) in the pathogenesis of the novel coronavirus infection COVID-19 induced by SARS-CoV-2. The exact pathogenesis of COVID-19 and the role of each component of innate and adaptive immunity are still unknown. Aim. Discussion of the possible role of TLRs in the immune response in COVID-19 infection. Results. Analysis of the literature in the PubMed database showed that the mechanism of penetration of SARS-CoV-2 and lysis of type II alveolocytes is the binding of the spike S-glycoprotein or capsid protein M of the virus to the receptor-binding domain of ACE2 on the surface of epithelial cells. Migration and infiltration of inflammatory cells leads to overactivation of TLR4 on the surface of alveolocytes and bronchial epithelium, shifting the process to MyD88-dependent acute inflammatory signaling and hypersecretion of proinflammatory cytokines that cause a “cytokine storm” and the development of severe complications of COVID-19 infection, in particular, acute respiratory infections, respiratory distress syndrome, pathology of internal organs, and, in some cases, the death of the patient. Conclusion. It is possible to suggest that TLRs have an impact on the immune response in COVID19 infection. Both antagonists and agonists of TLRs, depending on their type, can be examined to determine the therapeutic and negative effects of COVID-19 infection. Further research is needed to investigate TLRs and pathways for activating cytokine expression, as they indicate a direct relationship with mortality and virus susceptibility. Bioinformatic research can also help to better understand the interaction of TLRs with proteins and RNA of the SARS-CoV-2.

[1]  C. Jonsson,et al.  TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines , 2021, Nature Immunology.

[2]  N. Rezaei,et al.  Role of Toll‐like receptors in the pathogenesis of COVID‐19 , 2021, Journal of medical virology.

[3]  A. Cruz,et al.  Molecular and biophysical mechanisms behind the enhancement of lung surfactant function during controlled therapeutic hypothermia , 2021, Scientific reports.

[4]  J. P. de Rivero Vaccari,et al.  The Inflammasome in Times of COVID-19 , 2020, Frontiers in Immunology.

[5]  D. Jackson,et al.  Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model , 2020, bioRxiv.

[6]  Sarah M. Albogami,et al.  Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective , 2020, Saudi Pharmaceutical Journal.

[7]  Xingshun Xu,et al.  Reader response: Miller Fisher syndrome and polyneuritis cranialis in COVID-19 , 2020, Neurology.

[8]  S. Mukherjee,et al.  Targeting human TLRs to combat COVID‐19: A solution? , 2020, Journal of medical virology.

[9]  Eun-Kyeong Jo,et al.  COVID-19 Patients Upregulate Toll-like Receptor 4-mediated Inflammatory Signaling That Mimics Bacterial Sepsis , 2020, bioRxiv.

[10]  A. Vacca,et al.  Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment , 2020, Mediators of inflammation.

[11]  G. Tiram,et al.  Immune-mediated approaches against COVID-19 , 2020, Nature Nanotechnology.

[12]  Michael Berk,et al.  Genetic gateways to COVID‐19 infection: Implications for risk, severity, and outcomes , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  N. Rezaei,et al.  SARS‐CoV‐2: A comprehensive review from pathogenicity of the virus to clinical consequences , 2020, Journal of medical virology.

[14]  R. Mason Thoughts on the alveolar phase of COVID-19 , 2020, American journal of physiology. Lung cellular and molecular physiology.

[15]  Michael R Hamblin,et al.  The immune system and COVID-19: Friend or foe? , 2020, Life Sciences.

[16]  M. Triggiani,et al.  COVID 19: a clue from innate immunity , 2020, Immunologic research.

[17]  N. Rezaei,et al.  COVID-19: Developing from an Outbreak to A Pandemic , 2020, Archives of Medical Research.

[18]  S. Mukherjee,et al.  In silico studies on the comparative characterization of the interactions of SARS‐CoV‐2 spike glycoprotein with ACE‐2 receptor homologs and human TLRs , 2020, Journal of medical virology.

[19]  P. Welling,et al.  Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology. , 2020, Journal of the American Society of Nephrology : JASN.

[20]  F. Rincon,et al.  Status of SARS-CoV-2 in cerebrospinal fluid of patients with COVID-19 and stroke , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[21]  R. Bontrop,et al.  COVID-19 pandemic: is a gender-defined dosage effect responsible for the high mortality rate among males? , 2020, Immunogenetics.

[22]  R. Lodato,et al.  Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019 , 2020, Cardiovascular Pathology.

[23]  J. Benito-León,et al.  Miller Fisher syndrome and polyneuritis cranialis in COVID-19 , 2020, Neurology.

[24]  Cheng Wan,et al.  Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China , 2020, Kidney International.

[25]  M. Sohail,et al.  Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents , 2020, Virology journal.

[26]  Dingding Shen,et al.  Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? , 2020, The Lancet Neurology.

[27]  K. Hashimoto,et al.  Nervous system involvement after infection with COVID-19 and other coronaviruses , 2020, Brain, Behavior, and Immunity.

[28]  Gianpaolo Ronconi,et al.  Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. , 2020 .

[29]  Haibo Xu,et al.  Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer , 2020, Journal of Thoracic Oncology.

[30]  Jiyuan Zhang,et al.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.

[31]  N. Rezaei,et al.  Implications of Toll-like receptors in Ebola infection , 2017, Expert opinion on therapeutic targets.

[32]  T. Billiar,et al.  TLR4-Upregulated IL-1β and IL-1RI Promote Alveolar Macrophage Pyroptosis and Lung Inflammation through an Autocrine Mechanism , 2016, Scientific Reports.

[33]  A. Słońska,et al.  Mechanisms of endocytosis utilized by viruses during infection. , 2016, Postepy higieny i medycyny doswiadczalnej.

[34]  M. Katze,et al.  Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection , 2015, mBio.

[35]  Kui Li,et al.  Toll-Like Receptors in Antiviral Innate Immunity , 2013, Journal of Molecular Biology.